<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PEMETREXED</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PEMETREXED</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin)</span>,
                <span class="indication">First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin)</span>,
                <span class="indication">Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy)</span>,
                <span class="indication">Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult local protocol).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (toxicity in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises avoid if creatinine clearance less than 45&#8239;mL/minute&#8212;no information available.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Conjunctivitis, dehydration, gastro-intestinal disturbances, increased lacrimation, neuropathy, oedema, skin disorders,
              </p>
              <p>
                <strong>uncommon:</strong> Arrhythmias, colitis, interstitial pneumonitis,
              </p>
              <p>
                <strong>rare:</strong> Acute renal failure, hepatitis, peripheral ischaemia,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, Stevens-Johnson syndrome, thromboembolism, toxic epidermal necrolysis, tumour lysis syndrome, vomiting,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA124</h3>
              <p outputclass="title">Pemetrexed for the treatment of non-small cell lung cancer (August 2007)</p> <p>Pemetrexed is <b>not</b> recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.</p><xref format="html" href="http://www.nice.org.uk/TA124">www.nice.org.uk/TA124</xref>
                <a href="http://www.nice.org.uk/TA124" target="_blank">www.nice.org.uk/TA124</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA135</h3>
              <p outputclass="title">Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)</p> <p>Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.</p><xref format="html" href="http://www.nice.org.uk/TA135">www.nice.org.uk/TA135</xref>
                <a href="http://www.nice.org.uk/TA135" target="_blank">www.nice.org.uk/TA135</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA181</h3>
              <p outputclass="title">Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009)</p> <p>Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.</p><xref format="html" href="http://www.nice.org.uk/TA181">www.nice.org.uk/TA181</xref>
                <a href="http://www.nice.org.uk/TA181" target="_blank">www.nice.org.uk/TA181</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA190</h3>
              <p outputclass="title">Pemetrexed for the treatment of non-small cell lung cancer (June 2010)</p> <p>Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.</p><xref format="html" href="http://www.nice.org.uk/TA190">www.nice.org.uk/TA190</xref>
                <a href="http://www.nice.org.uk/TA190" target="_blank">www.nice.org.uk/TA190</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA309</h3>
              <p outputclass="title">Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (April 2014)</p> <p>Pemetrexed is <b>not</b> recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in patients whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.</p><xref format="html" href="http://www.nice.org.uk/TA309">www.nice.org.uk/TA309</xref>
                <a href="http://www.nice.org.uk/TA309" target="_blank">www.nice.org.uk/TA309</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes
          </li>
          <li>
            history of cardiovascular disease
          </li>
          <li>
            prophylactic folic acid supplementation required (consult product literature)
          </li>
          <li>
            prophylactic vitamin B<sub>12 </sub> supplementation required (consult product literature)
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>












      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PEMETREXED</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76041"><a href="../medicinalForm/PHP76041.html" data-target="#PHP76041" data-action="load">Powder for solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
